| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 641.84 | 26.6% |
| Total Income | 652.30 | 26.6% |
| Expenditure | 467.15 | 20.4% |
| PBT | 185.15 | 45.3% |
| Net Profit | 136.96 | 43.7% |
| OPM | 24.78% | 0.37pp |
| NPM | 21.00% | 2.19pp |
| EPS | 11.18 | 1333.3% |
Alivus Life Sciences Reports Strong Q3FY25 Results, Delivers 12% Revenue Growth, EBITDA Margins Expand to 31.3%
23 Jan 2025 · 23 Jan 2025, 08:01 pm
Summary
Alivus Life Sciences Limited, a leading developer and manufacturer of high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, announced its financial results for the quarter and nine months ended December 31, 2024. The company reported a YoY revenue growth of 12.0% and 26.6% QoQ, reaching Rs. 6,418 Mn in Q3FY25. EBITDA was at Rs. 2,008 Mn, a growth of 15.2% YoY and 40.5% QoQ. EBITDA margins stood at 31.3% for Q3FY25, up 90 bps YoY and 310 bps QoQ. The company generated a strong free cash flow of Rs. 1,838 Mn leading to Cash and Cash Equivalents of Rs. 4,993 Mn as of 31 December 2024.
Key Highlights
- 1
Revenue from operations for Q3FY25 reached Rs. 6,418 Mn, a growth of 12.0% YoY and 26.6% QoQ.
- 2
EBITDA for Q3FY25 was at Rs. 2,008 Mn, a growth of 15.2% YoY and 40.5% QoQ.
- 3
EBITDA margins for Q3FY25 were at 31.3%, up 90 bps YoY and 310 bps QoQ.
- 4
PAT for the quarter stood at Rs. 1,370 Mn with PAT margins at 21.3%.
- 5
The company generated a strong free cash flow of Rs. 1,838 Mn leading to Cash and Cash Equivalents of Rs. 4,993 Mn as of 31 December 2024.
Management Comments
Dr. Yasir Rawjee
MD & CEO, Alivus Life Sciences Limited
The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences. I am pleased to report that our Q3 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth. Our quest for high-quality, innovative solutions and scalability continues, in order to build a sustainable business over the long term.
Tushar Mistry
CFO, Alivus Life Sciences Limited
Our emphasis on achieving quality growth has delivered encouraging outcomes with highest ever quarterly revenue at Rs. 6,418 Mn. This translated to steady gross margins at ~56%, while our EBITDA grew by 15.2% YoY, underscoring our ability to cater a diversified product range while maintaining stringent cost efficiency.
Informational and educational content only. Not investment advice.